▽Beckman Coulter, Inc. ●01/30 06:14 Beckman Coulter Receives FDA Breakthrough Device Designation for Alzheimer's Disease Blood TestBeckman Coulter Diagnostics, a global leader in clinical diagnostics, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter’s Access p‑Tau217/β-Amyloid 1-42 plasma ratio. This blood test is designed to aid healthcare providers identify
▽Siemens Healthineers ●01/29 19:05 Press Event13 February 2025Siemens Annual Shareholders' Meeting 2025Here you will find the opening speeches of Jim Hagemann Snabe, Chairman of the Supervisory Board, and of Roland Busch, CEO.daysPress Event13 February 2025First Quarter Results FY 2025days